Comparative phenotypic profiling of the JAK2 inhibitors ruxolitinib, fedratinib, momelotinib, and pacritinib reveals distinct mechanistic signatures

• Jack W. Singer ,

  Roles Conceptualization, Resources, Supervision, Writing – original draft, Writing – review & editing

  * E-mail: SSGC.JWS@gmail.com

  Affiliations CTI BioPharma Corp., Seattle, Washington, United States of America, Elson Floyd College of Medicine, Washington State University, Seattle, Washington, United States of America

  http://orcid.org/0000-0003-4001-4549

  ⨯
• Suliman Al-Fayoumi,

  Roles Conceptualization, Resources, Writing – review & editing

  Affiliation CTI BioPharma Corp., Seattle, Washington, United States of America

  ⨯
• Jason Taylor,

  Roles Conceptualization, Resources, Writing – review & editing

  Affiliation CTI BioPharma Corp., Seattle, Washington, United States of America

  ⨯
• Sharlene Velichko,

  Roles Conceptualization, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – review & editing

  Affiliation Eurofins Discovery, Phenotypic Services, Burlingame, California, United States of America

  ⨯
• Alison O’Mahony

  Roles Conceptualization, Formal analysis, Investigation, Methodology, Validation, Visualization, Writing – review & editing

  Affiliation Eurofins Discovery, Phenotypic Services, Burlingame, California, United States of America

  ⨯